Zuranolone was approved for postpartum depression, not major depressive disorder

What the study found: The authors present zuranolone's approval for postpartum depression as a case study in recent drug regulation. They report that the drug was approved for postpartum depression in August 2023, while approval for major depressive disorder was denied.
Why the authors say this matters: The authors conclude that priority review, fast-track designation, and policy shifts intended to improve innovation and efficiency may lower the amount and type of evidence needed for approval. They suggest this may affect the balance between potential benefits and harms for newly approved medicines.
What the researchers tested: The authors examined the clinical trial data submitted by the manufacturer for zuranolone and discussed the regulatory review process. They also reviewed how the drug was handled by US regulatory bodies.
What worked and what didn't: The abstract says zuranolone received approval for postpartum depression after a 7-month process, aided by priority review and fast-track designation. It also says approval for major depressive disorder was denied, and that the approval framework allowed fewer trials and reliance on surrogate outcomes rather than clinically relevant outcomes.
What to keep in mind: The abstract does not provide the specific trial results or detailed reasons for the approval and denial decisions. It also does not describe limitations of the authors' analysis beyond noting that the article is a case study.

Key points

• Zuranolone was approved in August 2023 for postpartum depression.
• Approval for major depressive disorder was denied.
• The approval process took 7 months because the drug received priority review and fast-track designation.
• The authors say fast-track designation can allow fewer trials and reliance on surrogate outcomes.
• The abstract frames zuranolone as a case study in recent drug regulatory policy.